- Motley Fool•yesterday
Teva's oncology division could be on the chopping block.
- Business Wire•2 days ago
Teva Announces Publication of ARM-TD Study Results in Neurology® for the Investigational Use of Deutetrabenazine in Tardive Dyskinesia
Teva Pharmaceutical Industries Ltd. today announced the publication of results from the Phase II/III study ARM-TD in Neurology®, the medical journal of the American Academy of Neurology.
- Reuters•3 days ago
Merck & Co's cholesterol-reducing drug Vytorin faces competition for the first time ever after two companies announced progress on their generic versions of a drug that generated more than $1 billion in sales last year. The U.S. Food and Drug Administration on Wednesday approved Impax Laboratories Inc's generic version of Vytorin, while Teva Pharmaceutical Industries Ltd launched its generic version of the drug in the United States. Impax said it will immediately start commercialization for its generic version of Vytorin.
TEVA : Summary for Teva Pharmaceutical Industries - Yahoo Finance
Teva Pharmaceutical Industries Limited (TEVA)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||31.50 x 1000|
|Ask||31.95 x 1000|
|Day's Range||31.30 - 31.94|
|52 Week Range||30.22 - 56.44|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||451.14|
|Dividend & Yield||1.36 (4.23%)|
|1y Target Est||N/A|